These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 22011690)

  • 1. Plasma pharmacokinetics of daptomycin in critically ill patients with renal failure and undergoing CVVHD.
    Khadzhynov D; Slowinski T; Lieker I; Spies C; Puhlmann B; König T; Uhrig A; Eggers K; Neumayer HH; Traunmüller F; Joukhadar C; Peters H
    Int J Clin Pharmacol Ther; 2011 Nov; 49(11):656-65. PubMed ID: 22011690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of daptomycin in adult patients undergoing continuous renal replacement therapy.
    Xu X; Khadzhynov D; Peters H; Chaves RL; Hamed K; Levi M; Corti N
    Br J Clin Pharmacol; 2017 Mar; 83(3):498-509. PubMed ID: 27628437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative polymyxin B pharmacokinetics in critically ill patients with renal insufficiency and in continuous veno-venous hemodialysis.
    Surovoy YA; Burkin MA; Galvidis IA; Sobolev MA; Rende OC; Tsarenko SV
    Eur J Clin Pharmacol; 2023 Jan; 79(1):79-87. PubMed ID: 36378296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of daptomycin in critically ill patients.
    Soraluce A; Asín-Prieto E; Rodríguez-Gascón A; Barrasa H; Maynar J; Carcelero E; Soy D; Isla A
    Int J Antimicrob Agents; 2018 Aug; 52(2):158-165. PubMed ID: 29572042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis--a pharmacokinetic study.
    Kielstein JT; Eugbers C; Bode-Boeger SM; Martens-Lobenhoffer J; Haller H; Joukhadar C; Traunmüller F; Knitsch W; Hafer C; Burkhardt O
    Nephrol Dial Transplant; 2010 May; 25(5):1537-41. PubMed ID: 20031929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of daily daptomycin in critically ill patients undergoing continuous renal replacement therapy.
    Corti N; Rudiger A; Chiesa A; Marti I; Jetter A; Rentsch K; Müller D; Béchir M; Maggiorini M
    Chemotherapy; 2013; 59(2):143-51. PubMed ID: 24051895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and pharmacokinetic considerations for the use of daptomycin in patients with Staphylococcus aureus bacteraemia and severe renal impairment.
    Chaves RL; Chakraborty A; Benziger D; Tannenbaum S
    J Antimicrob Chemother; 2014 Jan; 69(1):200-10. PubMed ID: 24030545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of daptomycin in critically ill patients with various degrees of renal impairment.
    Grégoire N; Marchand S; Ferrandière M; Lasocki S; Seguin P; Vourc'h M; Barbaz M; Gaillard T; Launey Y; Asehnoune K; Couet W; Mimoz O
    J Antimicrob Chemother; 2019 Jan; 74(1):117-125. PubMed ID: 30295740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of mezlocillin and sulbactam under continuous veno-venous hemodialysis (CVVHD) in intensive care patients with acute renal failure.
    Rohde B; Werner U; Hickstein H; Ehmcke H; Drewelow B
    Eur J Clin Pharmacol; 1997; 53(2):111-5. PubMed ID: 9403281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple-dose pharmacokinetics of daptomycin during continuous venovenous haemodiafiltration.
    Wenisch JM; Meyer B; Fuhrmann V; Saria K; Zuba C; Dittrich P; Thalhammer F
    J Antimicrob Chemother; 2012 Apr; 67(4):977-83. PubMed ID: 22210754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation.
    Eyler RF; Heung M; Pleva M; Sowinski KM; Park PK; Napolitano LM; Mueller BA
    Pharmacotherapy; 2012 Dec; 32(12):1061-9. PubMed ID: 23208833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daptomycin serum levels in critical patients undergoing continuous renal replacement.
    Falcone M; Russo A; Cassetta MI; Lappa A; Tritapepe L; Fallani S; Vullo V; Venditti M; Novelli A
    J Chemother; 2012 Oct; 24(5):253-6. PubMed ID: 23182044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linezolid extracorporeal removal during haemodialysis with high cut-off membrane in critically ill patients.
    Villa G; Cassetta MI; Tofani L; Valente S; Chelazzi C; Falsini S; De Gaudio AR; Novelli A; Ronco C; Adembri C
    Int J Antimicrob Agents; 2015 Oct; 46(4):465-8. PubMed ID: 26315198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetic modeling of multiple-dose intravenous fosfomycin in critically ill patients during continuous venovenous hemodialysis.
    Hüppe T; Götz KM; Meiser A; de Faria Fernandes A; Maurer F; Groesdonk HV; Volk T; Lehr T; Kreuer S
    Sci Rep; 2023 Oct; 13(1):18132. PubMed ID: 37875513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daptomycin Pharmacokinetics and Pharmacodynamics in Patients on Methadone Substitution Therapy.
    De Gregori S; De Silvestri A; Molinaro MD; Monzillo V; Biscarini S; Colaneri M; Gallazzi I; Bartoli A; Bruno R; Seminari E
    Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):547-554. PubMed ID: 34231117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis.
    Vilay AM; Grio M; Depestel DD; Sowinski KM; Gao L; Heung M; Salama NN; Mueller BA
    Crit Care Med; 2011 Jan; 39(1):19-25. PubMed ID: 20890189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of Daptomycin in Critically Ill Pediatric Patients.
    Antachopoulos C; Ilia S; Kadiltzoglou P; Baira E; Dokoumetzidis A; Gikas E; Volakli E; Sdougka M; Briassoulis G; Roilides E
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29610198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and dialytic clearance of baricitinib during in vivo continuous venovenous haemodialysis in a patient with COVID-19.
    Palmer ME; Belcher RM; Engeleit A; Wenzler E; Bulman ZP; Benken ST
    Int J Antimicrob Agents; 2023 Sep; 62(3):106920. PubMed ID: 37442487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and safety of multiple doses of daptomycin 6 mg/kg in noninfected adults undergoing hemodialysis or continuous ambulatory peritoneal dialysis.
    Benziger DP; Pertel PE; Donovan J; Yankelev S; Schwab RJ; Swan SK; Cannon C
    Clin Nephrol; 2011 Jan; 75(1):63-9. PubMed ID: 21176752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects.
    Dvorchik BH; Brazier D; DeBruin MF; Arbeit RD
    Antimicrob Agents Chemother; 2003 Apr; 47(4):1318-23. PubMed ID: 12654665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.